Last updated on August 2018

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

Brief description of study

This will be a phase I clinical trial escalating dose testing AsiDNA administered intravenously (iv) as monotherapy. The aim of the study is to assess the safety, pharmacokinetics and pharmacodynamics and preliminary efficacy of AsiDNA in patients with solid tumors.

Clinical Study Identifier: NCT03579628

Contact Investigators or Research Sites near you

Start Over

Christophe LE TOURNEAU, MD

Institut Curie
Paris, France
  Connect »